Company Metrics

• 75 P/E
• 1.67 P/S
• 1 P/B
• -0.28 EPS
• 5.09% Cash ROIC
• 1.68 Cash Ratio
• 0 / 0% Dividend
• 29,995.00 Avg. Vol.
• 66.76M Shares
• 197.6M Market Cap.

Company Description

Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host organism, which in turn produces the protein of interest. Its products include WinRho SDF for treating immune thrombocytopenia, preventing hemolytic disease of the newborn, and infectious diseases causing a drop in blood platelets; HepaGam B for treating following hepatitis B exposure and following liver transplantation in hepatitis-B-positive patients; VariZIG used to prevent viral chickenpox infection; Vaccinia immune globulin intravenous for treating reactions associated with smallpox vaccinations; and Accretropin to normalize growth in children with growth hormone deficiency and girls with Turner syndrome. The company's Phase III clinical trial products comprise Botulism antitoxin heptavalent containing antibodies specific for the A, B, C, D, E, F, and G botulinum toxin types, as well as Anthrax immune globulin for treating inhalational anthrax; Phase I clinical trial product includes TST10088 for treating solid tumours. Its products under research/preclinical stage comprise Leucotropin for enhancing mature white-blood-cell production in stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma; Ricin immune globulin for treating ricin poisoning; Ebola/Marburg immune globulins for treating and preventing hemorrhagic fever; and anti-infective products for various conditions. In addition, Cangene Corporation provides contract research and development, and manufacturing services to other biopharmaceutical companies and government organizations. The company was founded in 1984 and is headquartered in Winnipeg, Canada.
less

Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host...
more

News